To CANCER IMMUNITY Home Page

Table 3

Most common adverse events for subjects evaluable for toxicity.

IL-12 Dose (ng/kg)

0

10

30

100

Administration Route
(number of subjects)

s.c.
(4)

i.v.
(3)

s.c.
(6)

i.v.
(3)

s.c.
(3)

i.v.
(3)

s.c.
(3)

i.v.
(3)

Event

Toxicity Gradea

Number of Patients Exhibiting Event

Fever

less than or equal to 2

-

-

2

-

-

3

-

3

3

-

-

-

-

-

-

-

-

Lethargy

less than or equal to 2

-

3

-

3

-

3

1

1

3

-

-

-

-

-

-

-

-

Nausea or vomiting

less than or equal to 2

-

3

-

1

1

2

3

-

3

-

-

-

-

-

1

-

-

Pain, including tumor pain

less than or equal to 2

1

3

-

-

1

3

2

1

3

-

-

-

-

-

-

-

1

Headache

less than or equal to 2

-

2

-

1

-

3

-

1

3

-

-

-

-

-

-

-

-

aUsing NCI CTC criteria. There were no grade IV toxicities.

 

Copyright © 2003 by Jonathan Cebon